Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: A phase II-study (NCT00356161)

BMC Gastroenterology

Research Article

Daniel Seehofer¹  Peter Neuhaus¹  Bernhard Gebauer²  Pjotr Podrabsky²  Maciej Pech³  Jens Ricke³  Marianne Sinn⁴  Annett Nicolaou⁴  Bernd Dörken⁴  Hanno Riess⁴  Bert Hildebrandt⁴ 

[1] CharitéCentrum für Chirurgische Medizin, Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Campus Virchow Klinikum, Charité Universitätsmedizin Berlin, Augustenburger Platz 1, D-13344, Berlin, Germany;CharitéCentrum für Tumormedizin, Klinik für Strahlenheilkunde, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, D-13344, Berlin, Germany;CharitéCentrum für Tumormedizin, Klinik für Strahlenheilkunde, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, D-13344, Berlin, Germany;Klinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-Universität Magdeburg, Leipziger Str. 44, D-30120, Magdeburg, Germany;CharitéCentrum für Tumormedizin, Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, D-13344, Berlin, Germany;

关键词: Hepatic arterial infusion;    Infusions;    Intra-arterial;    Liver neoplasms;    Hepatocellular cancer;    Biliary tract cancer;    Cholangiocellular carcinoma;    Natriumfolinate;    5-fluorouracil;    Oxaliplatin;   

DOI  :  10.1186/1471-230X-13-125

 received in 2012-11-23, accepted in 2013-08-01,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundHepatic arterial infusion (HAI) of chemotherapy requires the implantation of a transcatheter application system which is traditionally performed by surgery. This procedure, but particularly the adjacent drug application via pump or port is often hampered by specific complications and device failure. Interventionally implanted port catheter systems (IIPCS) facilitate the commencement of HAI without need for laparatomy, and are associated with favorable complication rates. We here present an evaluation of the most important technical endpoints associated with the use of IIPCS for HAI in patients with primary liver cancers.Methods70 patients (pts) with hepatocellular (HCC, n=33) and biliary tract cancer (BTC, n=37) were enrolled into a phase II –study. Of those, n=43 had recurrent disease and n=31 suffered from liver-predominant UICC-stage IVb. All pts were provided with IIPCSs before being treated with biweekly, intraarterial chemotherapy (oxaliplatin, 5-Flourouracil, folinic acid). The primary objective of the trial was defined as evaluation of device-related complications and port duration.ResultsImplantation of port catheters was successful in all patients. Mean treatment duration was 5.8 months, and median duration of port patency was not reached. Disease-progression was the most common reason for treatment discontinuation (44 pts., 63%), followed by chemotherapy-related toxicity (12 pts., 17%), and irreversible device failure (5 pts., 7%). A total of 28 port complications occurred in 21 pts (30%). No unexpected complications were observed.ConclusionsHAI via interventionally implanted port catheters can be safely applied to patients with primary liver tumors far advanced or/and pretreated.

【 授权许可】

Unknown   
© Sinn et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.